GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » PS Ratio

Athersys (Athersys) PS Ratio

: 1.13 (As of Today)
View and export this data going back to 2007. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Athersys's share price is $0.0045. Athersys's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Hence, Athersys's PS Ratio for today is 1.13.

Good Sign:

Athersys Inc stock PS Ratio (=1.2) is close to 1-year low of 1.2

The historical rank and industry rank for Athersys's PS Ratio or its related term are showing as below:

ATHXQ' s PS Ratio Range Over the Past 10 Years
Min: 0.51   Med: 336.29   Max: 25187.5
Current: 1.15

During the past 13 years, Athersys's highest PS Ratio was 25187.50. The lowest was 0.51. And the median was 336.29.

ATHXQ's PS Ratio is ranked better than
92.87% of 996 companies
in the Biotechnology industry
Industry Median: 8.985 vs ATHXQ: 1.15

Athersys's Revenue per Sharefor the three months ended in Sep. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00.

Warning Sign:

Athersys Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Athersys was -99.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 131.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 76.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 28.80% per year.

During the past 13 years, Athersys's highest 3-Year average Revenue per Share Growth Rate was 145.30% per year. The lowest was -82.50% per year. And the median was 14.40% per year.

Back to Basics: PS Ratio


Athersys PS Ratio Historical Data

The historical data trend for Athersys's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 206.90 854.17 229.06 36.69 1.88

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.07 1.88 5.35 96.67 108.03

Competitive Comparison

For the Biotechnology subindustry, Athersys's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Athersys's PS Ratio distribution charts can be found below:

* The bar in red indicates where Athersys's PS Ratio falls into.



Athersys PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Athersys's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0045/0.004
=1.13

Athersys's Share Price of today is $0.0045.
Athersys's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Athersys  (OTCPK:ATHXQ) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Athersys PS Ratio Related Terms

Thank you for viewing the detailed overview of Athersys's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (Athersys) Business Description

Traded in Other Exchanges
N/A
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Executives
Neema Mayhugh director 3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan director 100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo director, officer: Chief Executive Officer ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen officer: Chief Operating Officer 16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado officer: Interim, CFO 485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann officer: President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington director, officer: Chief Scientific Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell officer: Vice President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah director ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub director
Tadahisa Kagimoto director, 10 percent owner HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115